Methods for clinical research involving cannabis administration.

David A. Gorelick, Stephen J. Heishman

Research output: Contribution to journalArticle

Abstract

Better scientific understanding of cannabis effects and the development of treatments for cannabis dependence require clinical studies involving cannabis administration. Cannabis can be administered by smoking a plant-derived cigarette or by oral or intravenous administration of delta9-tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. The smoked route is most commonly used outside the laboratory, but is subject to wide variation in absorbed dose. Oral synthetic THC is a legally marketed medication (dronabinol), also subject to wide pharmacokinetic variation, but offering a greater safety margin because of slower onset of action and lower potency. Intravenous THC offers precise investigator control of dose and timing. Acute adverse effects of cannabis administration include tachycardia, orthostatic hypotension, pulmonary irritation (if smoked), motor incoordination, cognitive impairment, anxiety, paranoia, and psychosis. Screening of research subjects should identify and exclude those with risk factors for such events, e.g., a history of significant cardiovascular, pulmonary, or psychiatric disorders. Monitoring of subjects during cannabis administration should include heart rate, blood pressure, and mental status. Subjects should not be discharged from research participation until reevaluation has shown that they have returned to baseline status.

Original languageEnglish (US)
Pages (from-to)235-253
Number of pages19
JournalMethods in molecular medicine
Volume123
StatePublished - 2006
Externally publishedYes

Fingerprint

Cannabis
Dronabinol
Research
Marijuana Abuse
Research Subjects
Paranoid Disorders
Lung
Orthostatic Hypotension
Ataxia
Tachycardia
Tobacco Products
Intravenous Administration
Psychotic Disorders
Oral Administration
Psychiatry
Anxiety
Pharmacokinetics
Heart Rate
Smoking
Research Personnel

Cite this

Methods for clinical research involving cannabis administration. / Gorelick, David A.; Heishman, Stephen J.

In: Methods in molecular medicine, Vol. 123, 2006, p. 235-253.

Research output: Contribution to journalArticle

Gorelick, DA & Heishman, SJ 2006, 'Methods for clinical research involving cannabis administration.', Methods in molecular medicine, vol. 123, pp. 235-253.
Gorelick, David A. ; Heishman, Stephen J. / Methods for clinical research involving cannabis administration. In: Methods in molecular medicine. 2006 ; Vol. 123. pp. 235-253.
@article{39499f8b3ac144e6a51a7d59aee5b42e,
title = "Methods for clinical research involving cannabis administration.",
abstract = "Better scientific understanding of cannabis effects and the development of treatments for cannabis dependence require clinical studies involving cannabis administration. Cannabis can be administered by smoking a plant-derived cigarette or by oral or intravenous administration of delta9-tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. The smoked route is most commonly used outside the laboratory, but is subject to wide variation in absorbed dose. Oral synthetic THC is a legally marketed medication (dronabinol), also subject to wide pharmacokinetic variation, but offering a greater safety margin because of slower onset of action and lower potency. Intravenous THC offers precise investigator control of dose and timing. Acute adverse effects of cannabis administration include tachycardia, orthostatic hypotension, pulmonary irritation (if smoked), motor incoordination, cognitive impairment, anxiety, paranoia, and psychosis. Screening of research subjects should identify and exclude those with risk factors for such events, e.g., a history of significant cardiovascular, pulmonary, or psychiatric disorders. Monitoring of subjects during cannabis administration should include heart rate, blood pressure, and mental status. Subjects should not be discharged from research participation until reevaluation has shown that they have returned to baseline status.",
author = "Gorelick, {David A.} and Heishman, {Stephen J.}",
year = "2006",
language = "English (US)",
volume = "123",
pages = "235--253",
journal = "Methods in molecular medicine",
issn = "1543-1894",
publisher = "Humana Press",

}

TY - JOUR

T1 - Methods for clinical research involving cannabis administration.

AU - Gorelick, David A.

AU - Heishman, Stephen J.

PY - 2006

Y1 - 2006

N2 - Better scientific understanding of cannabis effects and the development of treatments for cannabis dependence require clinical studies involving cannabis administration. Cannabis can be administered by smoking a plant-derived cigarette or by oral or intravenous administration of delta9-tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. The smoked route is most commonly used outside the laboratory, but is subject to wide variation in absorbed dose. Oral synthetic THC is a legally marketed medication (dronabinol), also subject to wide pharmacokinetic variation, but offering a greater safety margin because of slower onset of action and lower potency. Intravenous THC offers precise investigator control of dose and timing. Acute adverse effects of cannabis administration include tachycardia, orthostatic hypotension, pulmonary irritation (if smoked), motor incoordination, cognitive impairment, anxiety, paranoia, and psychosis. Screening of research subjects should identify and exclude those with risk factors for such events, e.g., a history of significant cardiovascular, pulmonary, or psychiatric disorders. Monitoring of subjects during cannabis administration should include heart rate, blood pressure, and mental status. Subjects should not be discharged from research participation until reevaluation has shown that they have returned to baseline status.

AB - Better scientific understanding of cannabis effects and the development of treatments for cannabis dependence require clinical studies involving cannabis administration. Cannabis can be administered by smoking a plant-derived cigarette or by oral or intravenous administration of delta9-tetrahydrocannabinol (THC), the primary psychoactive chemical in cannabis. The smoked route is most commonly used outside the laboratory, but is subject to wide variation in absorbed dose. Oral synthetic THC is a legally marketed medication (dronabinol), also subject to wide pharmacokinetic variation, but offering a greater safety margin because of slower onset of action and lower potency. Intravenous THC offers precise investigator control of dose and timing. Acute adverse effects of cannabis administration include tachycardia, orthostatic hypotension, pulmonary irritation (if smoked), motor incoordination, cognitive impairment, anxiety, paranoia, and psychosis. Screening of research subjects should identify and exclude those with risk factors for such events, e.g., a history of significant cardiovascular, pulmonary, or psychiatric disorders. Monitoring of subjects during cannabis administration should include heart rate, blood pressure, and mental status. Subjects should not be discharged from research participation until reevaluation has shown that they have returned to baseline status.

UR - http://www.scopus.com/inward/record.url?scp=33646837088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646837088&partnerID=8YFLogxK

M3 - Article

VL - 123

SP - 235

EP - 253

JO - Methods in molecular medicine

JF - Methods in molecular medicine

SN - 1543-1894

ER -